LEM-S401
/ Lemonex
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 31, 2025
A First-In-Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM-S401, a Novel siRNA-DegradaBALL Drug Targeting CTGF in Healthy Adults.
(PubMed, Clin Transl Sci)
- P1 | "Trial Registration: ClinicalTrials.gov identifier: NCT04707131. https://clinicaltrials.gov/study/NCT04707131?cond=NCT04707131&rank=1."
Clinical • Journal • P1 data • Dermatology • Fibrosis • Immunology • Pain • CTGF
February 16, 2023
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=19 | Completed | Sponsor: Lemonex Inc. | Recruiting ➔ Completed
Trial completion
September 01, 2022
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Lemonex Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
1 to 3
Of
3
Go to page
1